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INTRODUCTION
Vitiligo is an acquired chronic skin disease, characterised
by progressing, usually symmetric, depigmented areas in
human skin. Vitiligo affects 0.5% of the human population.
Literature data demonstrate that more than 50% of patients
presenting with vitiligo are younger than 20 years (Taieb et
al., 2007; Taieb et al., 2010; Alikhan et al., 2011; Senft et
al., 2016). At this age vitiligo lesions influence the quality
of life and are a reason for psychological and emotional
stress, and social exclusion (Taieb et al., 2009; Whitton et
al., 2010). A dominating histological sign is a decreased
level or absence of melanin pigment in epidermal melano-
cytes provoked by autoimmune alterations. In the patho-
genesis of vitiligo, genetic, immune, and biochemical fac-
tors play crucial roles. Nowadays, multiple pathogenic
theories are proposed: neurological, autoimmune, self-de-
struction, genetic, and oxidative stress (Westerhof, 2007;
Iannella et al., 2016). Currently, the proposed therapy meth-
ods for vitiligo are divided into non-invasive and surgical
and are used in various combinations. The first group in-
cludes ultraviolet (UV) irradiation phototherapy, local
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Vitiligo is an acquired chronic skin disease, characterised by progressing, usually symmetric,
depigmented areas in human skin. Vitiligo affects 0.5% of the human population, however, opti-
mal treatment combination real clinical practice has yet to be found. The aim of the study was to
assess whether combined therapy with ultraviolet B (UVB) therapy and calcineurin inhibitors
(CNI) provides superior response in vitiligo patients, compared with phototherapy or topical CNI
monotherapy. We performed a retrospective cohort study of children treated for vitiligo from Janu-
ary 2016 to December 2019. Primary outcome measures include clinical efficacy defined by area
of repigmentation — good clinical efficacy (re-pigmentation of  50% of lesion surface area), posi-
tive clinical efficacy and poor clinical efficacy (re-pigmentation of < 15% of lesion surface area).
Secondary outcome measures included reduction of lesion size and tolerability of therapy. A total
of 114 patients were recruited in the study, 46 allocated to the topical CNI therapy group, 36 to
the narrow band (Nb-UVB), and 32 to the combined therapy group. All treatments statistically sig-
nificantly decreased lesion surface area compared to the baseline (mean, SD). Local therapy re-
duced lesions from 8.5 (5.7) to 5.3 (4.2) by 37.3% (p < 0.0001), phototherapy reduced lesions
from 9.8 (5.4) to 5.7 (3.92) by 42.3% (p < 0.0001), and combined therapy reduced lesions from
14.2 (4.8) to 6.58 (3.5) by 53.6% (p < 0.0001), with combined therapy showing superior numerical
efficacy. Clinical efficacy for CNI monotherapy was 67.4%, for phototherapy — 80.5%, and for
combined therapy 93.7%. The safety profile of therapies was consistent with other studies. Our
results support the use of combined therapy in vitiligo patients.
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immunomodulatory, immunosuppressive, photosensitising
treatment methods, and skin bleaching agents. The invasive
methods are autologous cell transplants, micropigmentation
or, on the contrary, laser assisted depigmentation proce-
dures. Complimentary therapies such as sunscreens, mask-
ing camouflage, psychotherapy can be applied (Gawkrodger
et al., 2008; Whitton et al., 2010).
In treatment of vitiligo, multiple factors need to be consid-
ered, such as age, activity stage, concomitant diseases, espe-
cially of autoimmune origin, previously applied methods of
treatment, as well as psychologic condition (Ongenae et al.,
2006; Taieb et al., 2013). Prior to initiation of therapy, other
autoimmune diseases are to be excluded, especially of the
thyroid gland, such as autoimmune polyendocrine syn-
drome. One of the current methods of pathogenic treatment
of vitiligo is UV phototherapy, particularly narrow band
(wave length 311 nm) ultraviolet B (UVB; TL-01 lamps)
and topical treatment to decrease inflammation caused by
immune factors (calcineurin inhibitors-CNI), which are in-
dicated and proved to be safe, especially in paediatric prac-
tice. It is important to provide treatment with non-invasive,
safe and effective methods of treatment that are well
adapted to patients of different age groups. Literature data
prove good clinical efficacy of topical CNI (tacrolimus
0.1% ointment and pimecrolimus 1% cream), as well as lo-
cal corticosteroids, in treatment of patients presenting with
vitiligo (Seirafi et al., 2007; Gawkrodger et al., 2008; Taieb
et al., 2013; Sisti et al., 2016). CNI promotes hyper-
pigmentation by modulation of immune response and influ-
encing melanocytes. Tacrolimus can supress the level of
TNF-, a key inflammatory cytokine, elevated levels of
which are found in vitiligo lesions and decrease production
of melanocytes (Moretti et al., 2002; Grimes et al., 2004;
Lan et al., 2005; Lee et al., 2013; Abyaneh et al., 2014).
Tacrolimus can stimulate proliferation of melanocytes via
stem cells present in vitiligo lesions in small quantities,
their migration through metalloproteases (MMP-a) and syn-
thesis of melanin (Moretti et al., 2002; Lan et al., 2005a;
2005b; Kang et al., 2009; Abyaneh et al., 2014).
Narrow band UVB phototherapy (Nb-UVB) is a pathogeni-
cally based method in treatment of vitiligo. UVB light in-
duces activation, proliferation and migration of melano-
cytes. Proliferation is induced by melanocyte growth factor
from keratinocytes (Wu et al., 2004; Hirobe et al., 2005).
Migration of melanocytes is stimulated by phosphorylated
focal adhesive molecules and matrix metalloproteinases —
MMP-2 (Lee et al., 2013; Abyaneh et al., 2014). Nb-UVB
induces also tyrosinase to produce melanin (Kang et al.,
2009). Nb-UVB mechanisms, which promote pigment pro-
duction, are dual. Light induces inactive melanocyte stem
cells in hair follicles and their activation, proliferation and
migration in affected skin (Cui et al., 1991). Proliferation is
induced by melanocyte growth factors like basic fibroblast
growth factor (bFGF) and endothelin-1 from keratinocytes.
There is a decrease of the bFGF level in vitiligo lesions. Mi-
gration of melanocytes is stimulated by phosphorylated fo-
cal adhesive kinases and expression of MMP-2 (Wu et al.,
2004). Nb-UVB alters the immunological response in the
case of vitiligo, and particularly induces production of IL-
10 in epidermis, that in turn ensures differentiation of T
regulatory cells. As a result, suppression of T-autoreactive
cells occurs (Ponsonby et al., 2005).
Nb-UVB modulates immunological response in the case of
vitiligo, and particularly induces production of IL-10 in epi-
dermis, that in turn ensures differentiation of T regulatory
cells. As a result, suppression of T-autoreactive cells occurs
(Lee et al., 2013). Nb-UVB can induce direct apoptosis of T
lymphocytes, similar to the process in psoriatic lesions
(Ponsonby et al., 2005; Lee et al., 2013).
This retrospective study aimed to assess whether combined
therapy with UVB and CNI provides superior response in
vitiligo patients, compared with phototherapy or topical
monotherapy.
MATERIALS AND METHODS
This is a retrospective cohort study based on review of med-
ical records from 114 patients diagnosed with vitiligo and
treated at the Rîga 1st Hospital. The study was approved by
the ethics review board of Rîga Stradiòð University. The
ICD-9 709.01 or ICD-10 L80 was used to identify patients
treated for vitiligo from 1 January 2016 to 31 December
2019. Patients were grouped based on received therapy:
group 1 – topical pimecrolimus cream two times a day,
group 2 – Nb-UVB phototherapy (311 nm UVB) and mois-
turising skin care cream three times a week, and group 3 –
combined therapy, treated with topical pimecrolimus cream
two times a day and Nb-UVB phototherapy in regimen
0.2–0.25 J/cm² three times a week, increasing by 5–20% in
every next procedure until obtaining moderate erythema, af-
ter that the dosage was fixed. Inclusion criteria were (a) di-
agnosis of vitiligo by a dermatologist, (b) initiation of
Nb-UVB (311 nm UVB) or topical calcineurin inhibitors
(CNI), or combined Nb-UVB with CNI, (c) age of < 18
years at the time of initiation of systemic therapy, and (d)
duration of follow-up of at least three months. Exclusion
criteria were (a) initiation of therapy prior to 1 January
2016, and (b) any missing data. Topical monotherapy was
administered to the patients diagnosed with clinically sig-
nificant comorbidities (metabolic syndrome, diabetes
mellitus, and diseases of the thyroid gland). Nb-UVB was
not applied to patients with Fitzpatrick skin phototype I, as
well as in patients with history of extensive insolation if
considered as a triggering factor for development of vitiligo.
This method was not used also in cases when vitiligo le-
sions were localised in the skin of the periorbital area. Data
were collected on demographics, clinical characteristics,
systemic therapy and treatment response. The therapy
method was assigned by the clinician based on clinical as-
sessment at initial presentation and/or failure of previous
therapies. The primary outcome measure was a comparison
of treatment efficacy between three groups, defined as posi-
tive clinical efficacy (re-pigmentation of  15% of the le-
sion surface area), good clinical efficacy (re-pigmentation
of  50% of the lesion surface area) and poor clinical effi-
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cacy (re-pigmentation of < 15% of the lesion surface area).
Clinical efficacy was defined by the sum of patients achiev-
ing a positive and good clinical efficacy rate. Secondary
outcome measures included reduction of lesion size and
tolerability of therapy. Treatment response was recorded ev-
ery month after initiation of therapy, and at the time of
treatment termination. Termination of treatment was de-
fined as discontinuing initial therapy. Lost to follow-up was
defined as no follow-up scheduled appointment at time of
data collection.
Variables were analysed using descriptive statistics. Quali-
tative variables were presented as counts and proportions
and compared across groups via the Pearson's chi-square
test for independence or Fisher's exact test as appropriate.
Quantitative variables were presented using means and stan-
dard deviations (SD) and compared using two-tailed tests if
normally distributed or as medians and interquartile ranges
and compared using the Wilcoxon rank-sum test if not nor-
mally distributed. Secondary outcome measures were sum-
marised by type of treatment. We compared the proportion
of patients in each group reporting improvement based on
skin lesion improvement, and reviewed side effects between
groups. A statistical significance threshold of p < 0.05 was
used. Statistical analyses were performed with SPSS ver-
sion 23.0 (IBM).
RESULTS
Demographic data are presented in Table 1, showing bal-
anced distribution per treatment arm. All treatments statisti-
cally significantly decreased lesion surface area compared
to the baseline (mean, SD). Local therapy reduced lesions
from 8.5 (5.7) to 5.3 (4.2) by 37.3% (p < 0.0001), photo-
therapy reduced lesions from 9.8 (5.4) to 5.7 (3.92) by
42.3% (p < 0.0001), and combined therapy reduced lesions
from 14.2 (4.8) to 6.58 (3.5) by 53.6% (p < 0.0001), with
combined therapy showing superior statistically significant
efficacy. Thus, combined therapy provided the most signifi-
cant reduction, shown in Figure 1. The impact of therapy on
lesion re-pigmentation was assessed (Table 2). Clinical effi-
cacy for CNI monotherapy was 67.4%, for phototherapy —
80.5%, and for combined therapy 93.7%. 75% of skin
re-pigmentation was achieved in 10.8% cases of topical
therapy, in 11.1% cases of CNI therapy, and in 12.5% of
cases for combined therapy. Pairwise comparison showed
superiority of phototherapy vs local therapy (p = 0.01),
combined therapy vs local therapy (p = 0.002) and com-
bined therapy vs phototherapy (p = 0.008). Duration of
vitiligo and patient age during the therapy had no impact on
response to therapy, measured as reduction of lesion size (p
> 0.05). No difference in clinical outcomes was observed
depending on patient gender (p = 0.353).
Comparing adverse drug reactions (ADR) between therapy
groups, in the local therapy group no ADR were observed,
in the phototherapy group one patient reported skin dryness
that disappeared after application of a moisturiser, two pa-
tients reported short-term itching, and one patient reported a
burning sensation that was managed by a moisturiser. In the
combined therapy group, moderate erythema was detected
in three patients, which quickly regressed after application
202 Proc. Latvian Acad. Sci., Section B, Vol. 75 (2021), No. 3.
Table 1. Patient demographic data and lesion distribution between therapy groups








Male 17 (37) 14 (38.9) 13 (40.6) 0.948
Female 29 (63) 22 (61.1) 19 (59.4)




14.13 ± 1.93 CI95%
[13.4;14.8]
0.075







Location of lesions, n (%)
Periorbital 9(19.6) 0(0) 0 (0)
Face 19 (41.3) 10 (27.8) 11 (34.4)
Body 18 (39.1) 36 (72.2) 21 (65.6)
Chest/trunk 24 (52.2) 15 18 (56.3)
Extremities 25 (47.8) 23 30 (93.8)
Skin phototype
1 4(8.7) 0 0(0) 0.043
2 41 (89.1) 33 32 (100)
3 1 (2.2) 3 0 (0)
Area of lesions, median (interquartile range) 8.5 (3.8–13.0) 9.5 (5.0–14.0) 15.0 (10.3–16.8) < 0.001
Duration of local therapy 5.43 (1.088) 5.31 (1.176) -
Duration of phototherapy – 30.03 (1.875) 29.47 (2.42)
Form of vitiligo, n (%)
vulgaris 34 (73.9) 23 (63.9) 32 (100) 0.001
segmentary 12 (26.1) 13 (36.1) 0 (0)
of topical dexpanthenol foam; one patient reported itchy
sensations that disappeared without additional intervention;
in one patient burning sensations were noticed and well
managed by a moisturiser. Reported ADR were non-serious
and all patients completed the assigned therapy course.
DISCUSSION
The data obtained and literature data demonstrate that Nb-
UVB phototherapy is clinically efficacious and a safe
method with no clinically significant side effects in treat-
ment of vitiligo patients in children and adolescent popula-
tions.
It is known that vitiligo treatment is more difficult for pa-
tients with lighter skin. Unlike other countries, individuals
with skin phototype 2 are dominating in Latvia, there are
only a small number of individuals with skin phototypes 3
and 1, and very few individuals with skin phototypes 4, 5,
and 6. Therefore, in our study, most patients had skin
phototype 2, and only four patients had the first skin photo-
type and four patients had the third skin phototype. Lighter
skin is associated with a higher risk of UVB therapy side ef-
fects.
By including individuals with mostly light-coloured skin in
our study, it was very important to find out whether therapy
for vitiligo would be less effective and whether there would
be more side effects compared with the description from
other authors. The effectiveness and safety of combined
therapy from UVB and locally applied calcineurin inhibitor
could thus be assessed.
The results of the current work support the trend of better
efficacy of combined therapy over monotherapy in patients
with large areas of lesions. For the first time, efficacy of
311 nm Nb-UVB phototherapy in vitiligo in paediatric pop-
ulation was described in 2000. According to published data,
51 patients in the age group from 4 till 16 presenting with a
generalised form of vitiligo were treated with 311 nm
Nb-UVB phototherapy in duration from 6 till 12 months.
The area of re-pigmentation of vitiligo lesions more than
75% was reached in 53% of cases (Njoo et al., 2000). Simi-
lar results were described by other authors, where re-pig-
mentation of more than 75% of vitiligo lesion surface was
reached accordingly in 50 and 75% paediatric population
patients treated with 311 nm Nb-UVB phototherapy
(Brazzeli et al., 2005; Kanwa et al., 2006). Chen et al.
(2005) found that 311 nm Nb-UVB phototherapy was effi-
cacious in more than 70% of children and adolescent
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Fig. 1. Lesion area before and after per therapy
group, p < 0.05.
Table 2. Evaluation of therapy efficacy
Results of treatment Local therapy group,
n = 46 (%)
Phototherapy group,
n = 36 (%)
Combined therapy group,
n = 32 (%)
Poor efficacy 15 (32.6) 7 (19.4) 2 (6.3)
Positive clinical efficacy 8 (17.4) 17 (47.2) 13 (40.6)
Good clinical efficacy 23 (50.0) 12 (33.3) 17 (53.1)
Percentage of reduction of the skin lesion area p < 0.05 37.3% 42.3% 53.6%
vitiligo patients with duration of treatment for 12 months.
CNI induces re-pigmentation, modulating immune response
by influencing melanocytes (Moretti et al., 2002; Grimes et
al., 2004; Lan et al., 2005; Lee et al., 2013). Interestingly,
tacrolimus decrease level of TNF- found in vitiligo lesions
in considerable amounts upregulate production of melanin
(Abyaneh et al., 2014). Publications indicate that in vitiligo
the combined treatment of CNI and 311 nm Nb-UVB
phototherapy shows better clinical efficacy. Results of an
investigation performed by Lotti et al. (2008) showed that
clinical efficacy was reached in 54.6% of cases by applying
pimecrolimus for six months, and in 76.5% of cases by ad-
ministering the combined method.
Similar results were obtained in this study. Combined ther-
apy showed significantly higher therapeutic efficacy com-
pared to UVB phototherapy and topical calcineurin inhibitor
therapy by evaluation of the percentage reduction of the
skin lesion area.
Clinical efficacy for CNI monotherapy was 67.4%, for
phototherapy — 80.5%, and for combined therapy 93.7%.
Both local therapy and Nb-UVB therapy had a relatively
high proportion of poor responders to therapy, compared to
the combined therapy group — 32.4%, 19.4%, and 6.3%,
respectively. 75% of skin repigmentation was achieved in a
limited proportion of patients: 10.8% cases for topical CNI
therapy, 11.1% for phototherapy, and 12.5% for combined
therapy. This finding highlights the need in vitiligo patients
for more efficacious treatment options. A previous compar-
ative study demonstrated a significant difference in  50%
re-pigmentation of facial lesions in vitiligo patients treated
with Nb-UVB phototherapy and pimecrolimus, in contrast
to Nb-UVB phototherapy and a placebo: 64.3% and 25.1%
(p < 0.05), respectively. Statistically significant and similar
results were shown in a study of Nb-UVB and tacrolimus
0.1% ointment (Esfandiarpour et al., 2009; Nordal et al.,
2011). The phototherapy and combined therapy related side
effects were generally mild and disappeared with moisturis-
ers, which outlines the favourable and manageable safety
profile desired in paediatric populations. With combined
therapy, no increase in ADR was observed. Side effects in
other studies showed comparable results to those detected in
our investigation — minor erythema, itch and burning sen-
sations (Njoo et al., 2000; Brazzeli et al., 2005; Tran et al.,
2005; Kanwa et al., 2006). To conclude, combined topical
CNI therapy with Nb-UVB course provides high response
rates, acceptable re-pigmentation results and a favourable
safety profile in real clinical practice.
CONCLUSIONS
The data from the study demonstrate that the combined
treatment method is statistically reliable and therefore rec-
ommended in clinical practice of dermatology.
To raise the therapeutic efficacy and to decrease the risk of
development of side effects, the combined method is recom-
mended in the treatment of vitiligo using Nb-UVB photo-
therapy and topical calcineurin inhibitor.
The combined method of treatment provides superior results
in comparison with monotherapy of topical calcineurin in-
hibitor or Nb-UVB phototherapy. Results of our compara-
tive study prove the safe use of CNI 1% pimecrolimus
cream in treatment of vitiligo patients. Monotherapy can be
applied in cases when there is intolerance or contraindica-
tions for Nb-UVB phototherapy.
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ÐAURA SPEKTRA UVB FOTOTERAPIJA UN LOKÂLO KALCINEIRÎNA INHIBITORU LIETOÐANA VITILIGO ÂRSTÇÐANAI
BÇRNIEM REÂLÂ KLÎNISKÂ PRAKSÇ
Vitiligo ir dzîves laikâ iegûta hroniska âdas slimîba, kurai raksturîga progresçjoðu, bieþi simetrisku, depigmentçu laukumu attîstîba âdâ.
Vitiligo skar 0,5% populâcijas, tomçr nav skaidrs, kâda ârstçðanas metoþu kombinâcija bûtu optimâlâkais variants. Pçtîjuma mçríis bija
novçrtçt, vai kombinçta ârstçðana ar UVB fototerapiju un kalcineirîna inhibitoriem nodroðina efektîvâku rezultâtu pacientiem ar vitiligo,
salîdzinâjumâ ar to, ja ðîs metodes bûtu lietotas katra atseviðíi. No 2016. gada janvâra lîdz 2019. gada decembrim mçs veicâm retrospektîvu
kohorta pçtîjumu bçrniem, kuri ârstçti ar vitiligo. Kâ primârais rezultâtu izvçrtçjuma râdîtâjs tika ietverta klîniskâ efektivitâte, kas tika
noteikta pçc sasniegtâs repigmentâcijas apgabala — laba klîniskâ efektivitâte (repigmentâcija  50% no bojâjuma virsmas laukuma),
pozitîva, bet vâja klîniskâ efektivitâte (atkârtota pigmentâcija < 15% no bojâjuma virsmas laukuma). Sekundârie rezultâtu izvçrtçjuma
parametri ietvçra bojâjuma laukuma mazinâðanos un terapijas panesamîbu. Kopuma pçtîjumâ tika iekïauti 114 pacienti. 46 pacientiem tika
nozîmçta tikai lokâlâ ârstçðana ar kalcineirîna inhibitoriem, 36 — tikai ðaura spektra UVB fototerapija un 32 — kombinçta terapija. Visas
ârstçðanas metodes statistiski nozîmîgi samazinâja bojâjuma virsmas laukumu, salîdzinot ar sâkotnçjo. Lokâlâ terapija samazinâja bojâjuma
laukumu no 8,5 (5,7) lîdz 5,3 (4,2) kopumâ par 37,3% (p < 0,0001), Fototerapija reducçja bojâjumus no 9,8 (5,4) lîdz 5,7 (3,92) kopumâ par
42,3% (p < 0,0001), un kombinçtâ terapija samazinâja bojâjumus no14,2 (4,8) lîdz 6,58 (3,5) kopumâ par 53,6% (p < 0,0001). Kombinçtâ
terapija uzrâdîja augstâku skaitlisko efektivitâti. Kalcineirîna inhibitoru monoterapijas klîniskâ efektivitâte bija 67,4%, fototerapijas —
80,5% un kombinçtâ terapijas — 93,7%. Terapijas droðuma profils bija analoìisks citiem pçtîjumiem. Mûsu pçtîjuma rezultâti apstiprina
kombinçtâs terapijas efektîvu pielietoðanu pacientiem ar vitiligo.
